Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Competitive
  3. /Pipeline Tracking

Competitive

Pipeline Tracking(6)

Monitor how competitors respond to market openings, data releases, and regulatory milestones across key franchises.

6 signals

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ScoreIntelligence Record
8.0

COMPETITIVE

FDA Supports Development of Psychedelic Drugs for Mental Health

The FDA is actively supporting the development of psychedelic drugs aimed at treating serious mental health conditions.

FDA·July 14, 2026
8.0

COMPETITIVE

Advances in NSP13 helicase inhibitors for broad-spectrum anti-coronavirus therapy

NSP13 helicase is a promising target for broad-spectrum anti-coronavirus drugs, with recent progress in inhibitor development.

Advances·July 9, 2026
8.0

COMPETITIVE

Novel bispecific T-cell engagers show promise against EGFR resistance in cancer

New bispecific T-cell engagers targeting EGFR escape variants show effective T cell-mediated cytotoxicity.

cetuximab·July 7, 2026
8.0

COMPETITIVE

mRNA-LNP Vaccine TP0435 Shows Promise Against Syphilis in Animal Models

The TP0435 mRNA-LNP vaccine demonstrated strong protective immunity against Treponema pallidum in rabbits, outperforming protein vaccines.

pharma companies in infectious diseases·mRNA-LNP·June 24, 2026
8.0

COMPETITIVE

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

The Pra-ffd hydrogel demonstrated improved bioavailability and reduced ocular inflammation in preclinical models.

Novartis·Ophthalmology·June 17, 2026
8.0

COMPETITIVE

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Merck has published a method for the large-scale synthesis of enlicitide decanoate, an investigational oral PCSK9 inhibitor.

Merck·Hyperlipidemia·June 16, 2026

Showing 1–6 of 6 records